
- Profil
- Soziale Medien
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘The Bristows team are a team to be reckoned with in the fields of life sciences and healthcare. They combine excellent technical knowledge with legal nous to achieve the commercial objectives of their clients, guiding them efficiently and effectively to a valuable result. ’
‘Charlie French is excellent to work with, intelligent and responsive, manages the team effectively with ease.'
- 'Chloe Dickson is a very bright senior associate who will go far: intelligent and commercial.'
- 'Chris Stubbs is a lawyer with a great future ahead of him; brilliant technical knowledge.’
‘Bristows has always been a leader in this sector. They really know their stuff and act in many of the leading cases. Individuals are hard-working, with strong technical understanding and careful attention to detail. Brian Cordery and Charlie French are key partners.’
‘Bristows has superb breadth and in-depth technological know-how. They are wonderful life sciences litigators and have been for decades.’
‘Liz Cohen and Brian Cordery stand out. They are extremely client-focused, understand the industry and client needs and provide nothing short of first-class service every time. ’
‘My experience is of Bristows' patent litigators, who are excellent. As a team, they are particularly good at a deep understanding of the relevant technology, and applying that knowledge to tactical advantage in litigation.'
Kernmandanten
- Syncona
- Telix Pharmaceuticals
- Bestway Panacea Holdings Limited
- Novartis Pharmaceuticals
- Sandoz
- Teva Pharmaceutical Industries
- Mara Renewables
- Genentech
- Touchlight
- AstraZeneca
Highlight-Mandate
- Advised AstraZeneca on a high profile patent deal with Chinese biotech Usynova to add to AstraZeneca’s oncology pipeline by licensing Usynova’s novel pancreatic cancer therapy in a transaction worth $420 million.
- Acting for Genentech and Novartis in ongoing UK High Court revocation and infringement proceedings against Celltrion in respect of Genentech’s and Novartis’s antibody medicine Xolair (ex-US sales $1.463 billion).
- Advising Syncona on the establishment and financing of ophthalmic gene therapy company Beacon Therapeutics, which launched in June 2023 following a £96 million Series A financing.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Führende Associates
Führende Associates sind regelmäßig an zentralen Mandaten des Teams beteiligt und erhalten positives Feedback von Wettbewerbern oder Mandanten.
Praxisleitung
Liz Cohen; Richard Dickinson
Weitere Kernanwält*innen
Brian Cordery; Robert Burrows; Greg Bacon; Rachel Mumby; Matthew Warren; Marek Petecki; Claire Smith; Alex Denoon; David Horner; Xisca Borrás; Ellen Lambrix; Charlie French; Nick Cross; Claire Phipps-Jones; Adrian Chew; Chloe Dickson; Chris Stubbs